Mike Quigley, Ph.D. - Bristol Myers Squibb Featured Researcher

Mike Quigley, Ph.D.

Mike Quigley, Ph.D.

Vice President and Head, Tumor Microenvironment Modulation Thematic Research Center

Site Head, Redwood City, CA


Mike currently serves as the vice president and head of the Tumor Microenvironment Modulation Thematic Research Center (TRC) at Bristol Myers Squibb, leading a team of talented scientists focused on developing new therapies at the intersection of tumor, stromal and immune biology within the tumor microenvironment (TME) to enhance responsiveness to checkpoint blockade and other targeted therapies in Redwood City, California. Mike also serves as the Redwood City site head, leading its research operations and focused on bringing innovation and streamlining to optimize operational efficiencies. In addition, Mike serves as the executive sponsor for California’s Bristol Myers Squibb Network of Women (B-NOW) people and business resource group (PBRG), focused on development and progression of women at the company.


Mike has spent his entire career focused on oncology drug discovery, both on the preclinical and translational sides. Prior to relocating to Redwood City, Mike worked at Bristol Myers Squibb’s Lawrenceville site, where he led a team of scientists focused on I-O biology discovery. He has also worked in oncology discovery at MedImmune and Janssen. Mike received a Bachelor’s of Science in Marine Biology from Eckerd College, before earning his Ph.D. in Immunology at Duke University. Mike completed his post-doctoral studies at Dana-Farber Cancer Institute’s Department of Pediatric Oncology. He is a member of the American Association of Immunologists (AAI) and the Society for Immunotherapy of Cancer (SITC) and serves on the Scientific Advisory Board of the Keystone Symposia.

Interests and Expertise

Once an aspiring marine biologist, Mike was inspired to change paths following his mother’s death from metastatic melanoma. He often thinks about his mother, whose diagnosis came long before the advent of immunotherapy, while he’s working to identify new I-O mechanisms. For Mike, data showing the benefits of I-O treatment for some patients are about more than just numbers, they’re about patients like his mom. He’s driven to understand the complexities of cancer so that more patients can have the potential to experience meaningful, long-term survival.


In his spare time, Mike likes to take advantage of the natural beauty that California has to offer. He can often be found with his wife and two daughters exploring the Bay Area, as they too share his love and appreciation for the wonders of nature.

Related Content

Scientists on the Move

Mike is back in Redwood City to lead a translational team focused on understanding mechanisms of I-O resistance.

Leading the I-O Resistance

Bristol Myers Squibb has built state-of-the-art labs dedicated to studying I-O resistance at our research sites in Redwood City and Cambridge.